Journal of Gastroenterology

, Volume 52, Issue 4, pp 432–443

Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial

Original Article—Alimentary Tract

Abstract

Background

The purpose of this study was to elucidate the effects of a dual-coated probiotic supplement (Duolac Care) on symptoms of diarrhea-predominant irritable bowel syndrome in a randomized double-blind clinical trial.

Methods

Fifty subjects with diarrhea-predominant irritable bowel syndrome were randomly assigned to either the non-coating group or the dual-coating group in order to receive two capsules per day of multi-species probiotics containing 5 billion bacteria per capsule for 4 weeks. Data from an adequate relief questionnaire were used in assessment of primary outcome. Daily records of stool frequencies and the Bristol stool scale, a weekly symptom diary using 100-mm visual analog scale, and Beck depression inventories were collected. Blood tests including blood cell counts, interleukin-10, tumor necrosis factor-alpha and inducible nitric oxide synthase, and regulatory T cells—CD4 + CD25high T cells, CD4 + LAP + T cells and CD25high + LAP + T cells—were analyzed before and after the study. The shift of gut microbiota was investigated using a quantitative real-time polymerase chain reaction assay.

Results

Responses to the adequate relief questionnaire indicated significant improvement in overall discomfort in the dual-coating group and the ratio of normal stools to hard or watery stools had a better effect from dual-coated probiotics compared to non-coated probiotics. This may be due to a shift of intestinal microbiota, as our correlation analysis showed significant negative correlation between Bifidobacterium and urgency of defecation.

Conclusions

Our result implies that dual-coating layers of probiotic supplement can be a candidate for treatment of diarrhea-predominant irritable bowel syndrome.

Keywords

Probiotics Irritable bowel syndrome Dual-coating technology 

Supplementary material

535_2016_1224_MOESM1_ESM.docx (33 kb)
Supplementary material 1 (DOCX 33 kb)

References

  1. 1.
    Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50(1):11–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Sayuk GS, Gyawali CP. Irritable bowel syndrome: modern concepts and management options. Am J Med. 2015;128(8):817–27.CrossRefPubMedGoogle Scholar
  5. 5.
    King T, Elia M, Hunter J. Abnormal colonic fermentation in irritable bowel syndrome. The Lancet. 1998;352(9135):1187–9.CrossRefGoogle Scholar
  6. 6.
    Schmulson M, Bielsa MV, Carmona-Sánchez R, et al. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. Rev de Gastroenterol de Méx. 2014;79(2):96–134 (English edition).Google Scholar
  7. 7.
    Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol: WJG. 2014;20(27):8886.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Minamida K, Nishimura M, Miwa K, et al. Effects of dietary fiber with Bacillus coagulans lilac-01 on bowel movement and fecal properties of healthy volunteers with a tendency for constipation. Biosci Biotechnol Biochem. 2015;79(2):300–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27(1):48–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126(6):1620–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121(3):580–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Burgain J, Gaiani C, Linder M, et al. Encapsulation of probiotic living cells: from laboratory scale to industrial applications. J Food Eng. 2011;104(4):467–83.CrossRefGoogle Scholar
  16. 16.
    Cha MK, Chung MJ, Kim JE, et al. Comparison of dual coated (Duolac™) and uncoated lactic acid bacteria from potential probiotics. Biotechnol Biotechnol Equip. 2011;25(3):2489–93.CrossRefGoogle Scholar
  17. 17.
    Kang JY, Lee DK, Park JE, et al. Dual coating improves the survival of proviotic bifidobacterium strains during exposure to simulated gastro-intestinal conditions. Korean J Microbiol. 2013;49(3):275–81.CrossRefGoogle Scholar
  18. 18.
    Yeun Y, Lee J. Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study. Arch Pharm Res. 2014;38(7):1–6.Google Scholar
  19. 19.
    Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders. Dig Dis Sci. 1995;40(5):986–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355(9209):1035–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Heaton K, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33(6):818–24.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL# 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(7):895–904.CrossRefPubMedGoogle Scholar
  23. 23.
    Beck AT, Steer RA, Carbin MG. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100.CrossRefGoogle Scholar
  24. 24.
    Guilarte M, Santos J, De Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Patacchioli F, Angelucci L, Dell’Erba G, et al. Actual stress, psychopathology and salivary cortisol levels in the irritable bowel syndrome (IBS). J Endocrinol Invest. 2001;24(3):173–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Cole JA, Rothman KJ, Cabral HJ, et al. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6(1):26.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kendall PC, Hollon SD, Beck AT, et al. Issues and recommendations regarding use of the beck depression inventory. Cogn Ther Res. 1987;11(3):289–99.CrossRefGoogle Scholar
  28. 28.
    Ringel Y, Ringel-Kulka T, Maier D, et al. Clinical trial: probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the symptoms of bloating in patients with functional bowel disorders—a double-blind study. J Clin Gastroenterol. 2011;45(6):518.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cappello C, Tremolaterra F, Pascariello A, et al. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis. 2013;28(3):349–58.CrossRefPubMedGoogle Scholar
  30. 30.
    Wong RK, Yang C, Song GH, et al. Melatonin regulation as a possible mechanism for probiotic (VSL# 3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015;60(1):186–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim S, Oh WY, Seung H, et al. Guideline for the clinical evaluation of drugs for the treatment of irritable bowel syndrome. Regul Res Food, Drug Cosmet. 2015;10(1):55–62.Google Scholar
  32. 32.
    FDA. Guidance for industry irritable bowel syndrome—clinical evaluation of drugs for treatment. US Department of Health and Human Sevices Food and Drug Administration Center for Drug Evaluation and Research. 2012.Google Scholar
  33. 33.
    Cryan JF, O’Mahony S. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23(3):187–92.CrossRefPubMedGoogle Scholar
  34. 34.
    Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105(05):755–64.CrossRefPubMedGoogle Scholar
  35. 35.
    Desbonnet L, Garrett L, Clarke G, et al. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008;43(2):164–74.CrossRefPubMedGoogle Scholar
  36. 36.
    O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Rho Jh, Wright DP, Christie DL, et al. A novel mechanism for desulfation of mucin: identification and cloning of a mucin-desulfating glycosidase (sulfoglycosidase) from Prevotella strain RS2. J Bacteriol. 2005;187(5):1543–51.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bergstrom KS, Xia L. Mucin-type O-glycans and their roles in intestinal homeostasis. Glycobiology. 2013:cwt045.Google Scholar
  39. 39.
    Ford A, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32(2):144–58.CrossRefPubMedGoogle Scholar
  40. 40.
    Triantafyllou K. Problems and challenges in the design of irritable bowel syndrome clinical trials. Focusing on the future with the experience from the past. Ann Gastroenterol. 2007;15(3):263–70.Google Scholar
  41. 41.
    Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. J neurogastroenterol Motil. 2014;20(2):163.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med. 1999;107(5):91–7.CrossRefGoogle Scholar
  43. 43.
    Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–90.CrossRefPubMedGoogle Scholar
  44. 44.
    Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008;51(12):1775–80.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Kyungsun Han
    • 1
  • Jinghwa Wang
    • 1
  • Jae-Gu Seo
    • 2
  • Hojun Kim
    • 1
  1. 1.Department of Rehabilitation Medicine of Korean MedicineDongguk University Ilsan HospitalGoyangRepublic of Korea
  2. 2.R&D Center, Cell Biotech Co. Ltd.GimpoRepublic of Korea

Personalised recommendations